Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2019-01-03
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects
NCT04107207
The Effects of Raspberry Leaf Tea on Blood Glucose Control
NCT06385626
Effect of an Extract of Green Tea on Adults With Type 2 Diabetes
NCT00389350
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
NCT00262145
Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring
NCT05832463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As a phase 0 clinical trial, we will learn how kombucha influences glucose metabolism in humans. We plan for 20 subjects to take part in this study.
This is a randomized-controlled counter-balanced study design. Subjects will be asked to complete 4 in-person visits over 2 months time (twice per month). At the first visit, subjects will be randomized into one of four groups. At each subsequent visit, subjects will be randomized into one of the remaining groups until they have completed each arm.
Arms (at least 5 subjects in each arm, minimum total=20 subjects)
1. Intervention group 1: commercial kombucha: drink 8oz kombucha
2. Intervention group 2: brewed kombucha: drink 8oz kombucha
3. Control group: drink 8oz tea (the same type as used to brew the kombucha)
4. Control group 2: drink 8oz tap water
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group 1: commercial kombucha
8oz
Commercial kombucha tea
Commercially-available kombucha tea.
Intervention group 2: brewed kombucha
8oz
Brewed kombucha tea
Kombucha tea brewed
Control group 1: tea
8oz
Control: Tea
Tea brewed in our lab.
Control group 2: water
8oz
Control: Water
Tap water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Commercial kombucha tea
Commercially-available kombucha tea.
Brewed kombucha tea
Kombucha tea brewed
Control: Tea
Tea brewed in our lab.
Control: Water
Tap water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English-speaking
* Have transportation to campus
* Overweight (BMI \>= 25 kg/m2) or obese (BMI \>=30 kg/m2)
Exclusion Criteria
* A diagnosis of any of the following:
* Diabetes (type 1 or 2)
* Cancer
* COPD
* Chronic alcoholism
* Peripheral vascular disease
* Autoimmune disease
* Chronic kidney disease
* Pregnant or breastfeeding
* Prescribed medication for insulin, glucose-lowering drugs, or steroids, such as prednisone
* Have routinely taken prebiotic or probiotic supplements in the past 3 months
* Have routinely consumed any of the following more than one time per week in the past month: kombucha, kefir, yogurt, kimchi, cottage cheese, raw apple cider vinegar (with the "mother"), sauerkraut, kvass.
30 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Missouri-Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julie Kapp
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie M Kapp, MPH, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Missouri
Columbia, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014707
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.